-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, Chengdu High-tech Zone has been in a stable position for many years in the comprehensive competitiveness ranking of China's biomedical parks, and has become a new highland for the development of the national biomedical industry
.
According to data, in the first three quarters of 2021, the total output value of the planned bio-manufacturing industry in Chengdu High-tech Zone increased by more than 14%, and the revenue of key enterprises in the planned biotechnology research and development and biological inspection industries increased by more than 30%
.
Chengdu Biomedicine is maintaining steady and rapid growth, showing strong development resilience
.
The author was informed that since November this year, biomedical companies in the Chengdu High-tech Zone have also reported new developments
.
For example, on November 5, Shamrock Bio was officially listed on the main board of the Stock Exchange of Hong Kong Limited, marking that Chengdu’s listed companies in the field of biomedicine have added "new faces"; on November 3, Yuanda Shuyang Pharmaceutical Human Fibrinogen The product has obtained the drug registration certificate issued by the National Medical Products Administration.
Yuanda Shuyang Pharmaceutical's human fibrinogen (Shuyang Yinyuan®) will be on the market soon.
.
.
Each and every new news is coming, and it also indicates that the Chengdu High-tech Zone Bio The rapid development of medicine
.
It is understood that since the beginning of this year, the varieties of innovative drugs in Chengdu High-tech Zone have also continued to emerge, and two new Class I drugs have been approved for listing
.
Among them, Huahao Zhongtian Youti Delong injection has become a domestic approved epothilone anti-tumor drug, and its first year output value is expected to exceed 100 million yuan; Chengdu Microchip Pharmaceutical's new-generation insulin sensitizer candidate drug Siglipta Sodium has become the world's first PPAR full agonist, a single drug used to treat type II diabetes with poor diet and exercise control
.
Up to now, the Chengdu High-tech Zone has a total of 48 Class I new drugs under development in the clinical stage
.
The biopharmaceutical industry is one of the three leading industries in Chengdu High-tech Zone, and has formed a good industrial foundation and a large industrial scale
.
In recent years, Chengdu High-tech Zone has been actively building a biomedical industry ecosystem, and has successively introduced a series of policies to promote the development of the biomedical industry, attracting a large number of biomedical industry companies to settle down.
.
For example, more than 3,000 pharmaceutical companies such as Sanofi, Gilead, Medtronic, AstraZeneca, Thermo Fisher, Allergan, and Boston Scientific have gathered in the area, attracting 7 Nobel Prize teams and more than 100 national teams.
After the meeting, there are 10 companies, and the scale of the biological industry has maintained a growth rate of more than 20% for 4 consecutive years
.
It is understood that in the field of biomedicine industry, Chengdu High-tech Zone aims to build a modern bio-industry system with international competitiveness and regional driving force.
It is accelerating the establishment of the “International Clinical Research Service Center for Drugs and Medical Devices” and “Global Production of Biotechnology Drugs”.
"Five Centers", "Sichuan Chengdu International Medical Center", "Global New Drug R&D Outsourcing Service Trading Center", and "Global Biomedicine Supply Chain Service Center"
.
In recent years, Chengdu's biomedical industry has achieved gratifying results.
In the first three quarters of this year, the biomedical companies in Chengdu High-tech Zone also performed well, with the total output value of the bio-manufacturing industry increasing by 14.
2%
.
Since this year, the "Chengdu Legion" has continued to emerge in the capital market
.
In addition to the above-mentioned clover biology, Haichuang Pharmaceutical, Connoa, Shengnuo Biological, Olin Biological, etc.
have also been listed, and the listing camp of Chengdu biomedical companies is continuously expanding
.
.
According to data, in the first three quarters of 2021, the total output value of the planned bio-manufacturing industry in Chengdu High-tech Zone increased by more than 14%, and the revenue of key enterprises in the planned biotechnology research and development and biological inspection industries increased by more than 30%
.
Chengdu Biomedicine is maintaining steady and rapid growth, showing strong development resilience
.
The author was informed that since November this year, biomedical companies in the Chengdu High-tech Zone have also reported new developments
.
For example, on November 5, Shamrock Bio was officially listed on the main board of the Stock Exchange of Hong Kong Limited, marking that Chengdu’s listed companies in the field of biomedicine have added "new faces"; on November 3, Yuanda Shuyang Pharmaceutical Human Fibrinogen The product has obtained the drug registration certificate issued by the National Medical Products Administration.
Yuanda Shuyang Pharmaceutical's human fibrinogen (Shuyang Yinyuan®) will be on the market soon.
.
.
Each and every new news is coming, and it also indicates that the Chengdu High-tech Zone Bio The rapid development of medicine
.
It is understood that since the beginning of this year, the varieties of innovative drugs in Chengdu High-tech Zone have also continued to emerge, and two new Class I drugs have been approved for listing
.
Among them, Huahao Zhongtian Youti Delong injection has become a domestic approved epothilone anti-tumor drug, and its first year output value is expected to exceed 100 million yuan; Chengdu Microchip Pharmaceutical's new-generation insulin sensitizer candidate drug Siglipta Sodium has become the world's first PPAR full agonist, a single drug used to treat type II diabetes with poor diet and exercise control
.
Up to now, the Chengdu High-tech Zone has a total of 48 Class I new drugs under development in the clinical stage
.
The biopharmaceutical industry is one of the three leading industries in Chengdu High-tech Zone, and has formed a good industrial foundation and a large industrial scale
.
In recent years, Chengdu High-tech Zone has been actively building a biomedical industry ecosystem, and has successively introduced a series of policies to promote the development of the biomedical industry, attracting a large number of biomedical industry companies to settle down.
.
For example, more than 3,000 pharmaceutical companies such as Sanofi, Gilead, Medtronic, AstraZeneca, Thermo Fisher, Allergan, and Boston Scientific have gathered in the area, attracting 7 Nobel Prize teams and more than 100 national teams.
After the meeting, there are 10 companies, and the scale of the biological industry has maintained a growth rate of more than 20% for 4 consecutive years
.
It is understood that in the field of biomedicine industry, Chengdu High-tech Zone aims to build a modern bio-industry system with international competitiveness and regional driving force.
It is accelerating the establishment of the “International Clinical Research Service Center for Drugs and Medical Devices” and “Global Production of Biotechnology Drugs”.
"Five Centers", "Sichuan Chengdu International Medical Center", "Global New Drug R&D Outsourcing Service Trading Center", and "Global Biomedicine Supply Chain Service Center"
.
In recent years, Chengdu's biomedical industry has achieved gratifying results.
In the first three quarters of this year, the biomedical companies in Chengdu High-tech Zone also performed well, with the total output value of the bio-manufacturing industry increasing by 14.
2%
.
Since this year, the "Chengdu Legion" has continued to emerge in the capital market
.
In addition to the above-mentioned clover biology, Haichuang Pharmaceutical, Connoa, Shengnuo Biological, Olin Biological, etc.
have also been listed, and the listing camp of Chengdu biomedical companies is continuously expanding
.
